Teva Pharmaceutical Industries Ltd (TEVJF) Other Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVJF) has 18 years of Other Non-Current Liabilities data on file, last reported at $3.8 billion in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 3.73% year-over-year to $3.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.8 billion (down 3.73% YoY) and the FY2025 annual result came in at $3.8 billion, down 5.46% from the prior year.
• Other Non-Current Liabilities improved to $3.8 billion in Q2 2026, from $3.7 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.4 billion in Q2 2024 to a low of $3.3 billion in Q1 2022.
• A 5-year average of $3.9 billion and a median of $3.9 billion in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 75.17% — and 2025, when it declined 15.65%.
• Tracing TEVJF's Other Non-Current Liabilities over 5 years: stood at $3.9 billion in 2022, then increased by 1.88% to $4.0 billion in 2023, then climbed by 0.22% to $4.0 billion in 2024, then dropped by 5.46% to $3.8 billion in 2025, then dropped by 0.45% to $3.8 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.8 billion (Q2 2026), $3.7 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.